Email Verification

Posted on 05/21/2015 in Uncategorized

[email_verification]

Former Chairman of the Joint Chiefs of Staff U.S. General Peter Pace joins Pathway Genomics Board of Directors

Posted on 05/19/2015 in News, Press Releases

U.S. General Peter Pace
San Diego, CA – May 19, 2015 - Pathway Genomics Corporation, a data-driven global healthcare company and precision medicine clinical laboratory announced today that the sixteenth Chairman of the Joint Chiefs of Staff, retired U.S. Marine General Peter Pace is joining the company’s Board of Directors.  

Jim Plante, Founder and CEO of Pathway Genomics, Appointed by US Secretary of Commerce and US Trade Secretary to Industry Trade Advisory Committee (ITAC)

Posted on 05/14/2015 in News, Press Releases

Jim Plante - Pathway Genomics
SAN DIEGO, CA / Washington DC May 14, 2015 – Pathway Genomics Corporation, a data-driven global healthcare company and global clinical laboratory, today announced that Founder and CEO Jim Plante has been appointed by the U.S. Secretary of Commerce, Penny Pritzker, and U.S. Trade Representative (USTR), Ambassador Michael Froman to the Industry Trade Advisory Committee on Chemicals, Pharmaceuticals, Health and Science Products (ITAC 3).  

Ask the Expert: An Interview with a Pathway Genomics’ Registered Dietitian

Posted on 04/29/2015 in Blog Post, GC

Mandy-Kenyon_An_Interview_wRD
Mandy Kenyon, MS, RD, CSSD

SAN DIEGO, Apr 29, 2015  — Mandy Kenyon, MS, RD, CSSD, is Pathway Genomics’ Registered Dietitian and played a major role in developing the customized diet plans that are part of tests such as Pathway Fit. Mandy is available to answer nutrition- and diet-related questions for Pathway’s clients and customers—contact her at rd@pathway.com.

Mandy recently shared a couple of the most common questions she receives in her work as a dietitian, as well as her responses:

Q: I have a healthy diet, no history of heart disease in my family, and I am overweight but not obese—do I really need to exercise? A: Absolutely. Being overweight (a BMI of 25.0–29.9) can have consequences, such as an increased risk of coronary heart disease, high blood pressure, stroke, and type II diabetes. Exercise can reduce these risks, and may improve both your current and future health by lessening the chance of complications later on.  

Ask The Expert: An Interview with a Pathway Genomics Counselor

Posted on 04/17/2015 in Blog Post, News

Ask The Expert - Leslie Ordal

SAN DIEGO, Apr 17, 2015  — Leslie Ordal, M.Sc., a field genetic counselor at Pathway Genomics, answers some frequently asked questions:

Are all genetic changes harmful?

No. In fact, everyone has genetic changes – it’s why we’re all different. Some genetic changes, called pathogenic variants, can be harmful to an individual, and in some cases, to their children if passed down.

Leslie Ordal, M.Sc
Many other genetic changes; however, are quite common and have no known effect on health – we call these benign variants, and they’re just part of natural human variation. Some genetic changes can even be beneficial, such as those associated with reduced risk for certain diseases like Alzheimer disease. Can I fix a pathogenic variant in my genes? This is a very common question, and right now the answer is no. Your genes are in almost every cell in your body, and there’s just no way to go in and fix an alteration in the genetic code in each and every cell. However, research is ongoing and may make this a possibility in the future.  

Pathway Genomics Launches Updated Next Generation Sequencing Tests for Colorectal Cancer

Posted on 03/26/2015 in News, Press Releases

Pathway Genomics ColoTrue and LynchTrue Syndrome
SAN DIEGO, Mar 26, 2015 (BUSINESS WIRE) -- Pathway Genomics Corporation, a forward-thinking big data healthcare company and global precision medicine clinical laboratory, announced it has launched ColoTrue™, a comprehensive panel that combines next-generation sequencing with deletion/duplication analysis to detect pathogenic variants in 15 high-risk colorectal cancer susceptibility genes. Pathway has also launched a smaller panel, LynchSyndromeTrue™, which tests for Lynch syndrome, the most common form of hereditary colon cancer.  

Pathway Genomics Appoints Former Cedars-Sinai Chair of Medicine Glenn D. Braunstein, M.D., as Chief Medical Officer

Posted on 03/11/2015 in News, Press Releases

braunstein
San Diego, CA – March 11, 2015 – Pathway Genomics Corporation, a forward-thinking big data healthcare company and global precision medicine clinical laboratory, has announced that endocrinologist Dr. Glenn D. Braunstein is the company’s new Chief Medical Officer. Dr. Braunstein takes on the role after serving on Pathway Genomics’ Strategic Advisory Board. With a special interest in pharmacogenomics, Dr. Braunstein’s first priority will be Pathway Genomics’ pharmacogenomic testing menu.  

Obesity, Genes and Aging….Overlapping Magisterium?

Posted on 03/10/2015 in Blog Post, Editorial

Chief Medical Officer

By Michael Nova, M.D.
Chief Innovation Officer
Pathway Genomics

There has recently (2013-15) been a flurry of human clinical trial publications regarding gene-diet interactions, primarily concerning obesity and related phenotypes.

A new finding by the Genetic Investigation of Anthropometric Traits, or GIANT, consortium has identified 97 gene regions associated with obesity, tripling the number of such genes previously known.  

Former Speaker of the House Newt Gingrich Joins Pathway Genomics’ Advisory Board

Posted on 02/26/2015 in News, Press Releases

Gingrich
SAN DIEGO, CAFebruary 26, 2015Pathway Genomics Corporation, a CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that former Speaker of the U.S. House of Representatives Newt Gingrich has joined its strategic advisory board. A former candidate for president of the United States in 2012, Gingrich has spent more than four decades as a leader in American public life. During his time in Congress, he helped save Medicare from bankruptcy, shepherded FDA reform to help the seriously ill and initiated a new focus on scientific research, prevention and wellness.  

Pathway Genomics Appoints Anja Kammesheidt as Vice President of Research and Development

Posted on 02/19/2015 in News, Press Releases

Vice President of Research and Development
SAN DIEGO, CAFebruary 19, 2015 – Pathway Genomics Corporation, a CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced it has named Anja Kammesheidt, Ph.D., as its vice president of research and development. Based at Pathway Genomics’ San Diego headquarters, Dr. Kammesheidt brings more than 15 years of experience to the role. “We are honored to have Dr. Kammesheidt join our organization where she will oversee all assay development activities,” said Jim Plante, Pathway Genomics’ founder and CEO. “We know that her wealth of knowledge will be a major asset to the company and a vital component of reaching our commercial objectives as we move forward.”  

Twitter Stream


Recent Posts

Search Posts